ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
LLY
|
Relapsed/refractory chronic lymphocytic leukemia
|
Approved
|
2023-01-27 00:00:00
|
FDA Approved on January 27, 2023.
| 1 |
TAK
|
Narcolepsy
|
Phase 2
|
2021-10-05 00:00:00
|
Phase 2 trial stopped dosing and ended trial due to emergence of a safety signal, noted October 5, 2021.
| -1 |
IFRX
|
ANCA-associated vasculitis (AAV)
|
Phase 2
|
2021-05-11 00:00:00
|
Phase 2 data released May 11, 2021 - safe and well tolerated
| 1 |
AZN
|
Bladder cancer
|
Phase 3
|
2020-03-06 00:00:00
|
Phase 3 data did not meet primary endpoint.
| 1 |
IONS
|
Chronic hepatitis B virus (CHB)
|
Phase 2b
|
2022-06-27 00:00:00
|
Phase 2b data readout reported that up to 68% of patients on NA therapy and up to 65% of patients not on NA achieved HBsAg <100 IU/mL at the end of treatment, noted June 27, 2022.
| 1 |
LLY
|
Medullary thyroid cancer (MTC)
|
Phase 3
|
2023-10-21 00:00:00
|
Phase 3 data presented at ESMO reported that selpercatinib demonstrated superior PFS vs control in the ITT-pembro (HR: 0.465, 95% CI: 0.309, 0.699; p-value: 0.0002) and ITT populations (HR: 0.482, 95% CI: 0.331, 0.700; p-value: 0.0001), noted October 21, 2023.
| 1 |
AMGN
|
Chronic spontaneous urticaria
|
Phase 2b
|
2023-10-31 00:00:00
|
Phase 2b trial did not meet its primary endpoint, noted October 31, 2023.
| 1 |
AGIO
|
Thalassemia
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data reported durable improvements in hemoglobin concentration and markers of hemolysis and ineffective erythropoiesis were observed for up to 72 weeks of treatment in both α- and β-thalassemia patients, noted December 12, 2022.
| 1 |
NVS
|
Non-small cell lung cancer (NSCLC), adjuvant
|
Phase 3
|
2022-08-15 00:00:00
|
Phase 3 trial did not meet the primary endpoint, noted August 15, 2022.
| 1 |
GLMD
|
HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)
|
Phase 2
|
2018-02-14 00:00:00
|
Phase 2 top-line data released February 14, 2018 did not meet primary endpoint.
| 1 |
JNJ
|
Multiple myeloma
|
Approved
|
2023-08-10 00:00:00
|
Approved August 10, 2023.
| 1 |
NVS
|
Acute myeloid leukemia (AML)
|
Approved
|
2017-04-28 00:00:00
|
Priority review granted November 14, 2016. Approval announced April 28, 2017.
| 1 |
BGNE
|
Nasopharyngeal cancer (RM-NPC)
|
Phase 3
|
2022-04-19 00:00:00
|
Additional Phase 3 data reported that progression-free survival was 15.5 months, noted April 19, 2022.
| 0 |
APLT
|
Diabetic cardiomyopathy (DbCM)
|
Phase 3
|
2023-06-22 00:00:00
|
Phase 3 baseline data to be presented at ADA showed a strong statistical correlation between elevations in the cardiac stress biomarker, NT-proBNP, reduced cardiac functional capacity and physical activity, underscoring the importance of early diagnosis via NT-proBNP and impact of DbCM on physical function and quality of life, noted June 22, 2023
| 1 |
NBIX
|
Huntington's disease
|
Approved
|
2023-08-18 00:00:00
|
Approved August 18, 2023.
| 1 |
TVTX
|
Classical homocystinuria (HCU)
|
Phase 1/2
|
2023-05-31 00:00:00
|
Additional Phase 2 data reported that treatment was well tolerated, with dose-dependent reductions in tHcy as previously observed in the highest BIW dosed cohorts, noted July 6, 2023.
| 1 |
INVA
|
cIAI (complicated intra-abdominal infections)
|
Approved
|
2018-08-27 00:00:00
|
FDA approval announced August 27, 2018.
| 1 |
INCY
|
Alopecia Areata
|
Approved
|
2022-06-14 00:00:00
|
Approved June 14, 2022.
| 1 |
EVO
|
High adenosine signature cancers
|
Phase 1
|
2023-04-19 00:00:00
|
Phase 1 objectives were achieved in a healthy volunteer study, confirming pharmacokinetics, pharmacodynamics, safety, and tolerability, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study in combination with a PD-1 inhibitor in patients with RCC and NSCLC, noted April 19, 2023
| 1 |
APM
|
Neuroblastoma
|
Phase 1/2
|
2023-06-22 00:00:00
|
Phase 1b/2a trial has been repurposed for small molecule drug , noted June 22, 2023.
| 0 |
AGIO
|
Pyruvate Kinase Deficiency
|
Phase 3
|
2022-06-10 00:00:00
|
Phase 3 new patient outcome reported that 28/78 (35.9%) of all patients achieved a normal hemoglobin level at least once during treatment, noted June 10, 2022.
| 1 |
SELB
|
Chronic Refractory Gout
|
Phase 3
|
2023-03-21 00:00:00
|
Phase 3 top-line data reported that both trials met their primary endpoints, noted March 21, 2023.
| 0 |
GKOS
|
Progressive keratoconus
|
Phase 3
|
2021-02-25 00:00:00
|
Phase 3 trial met primary endpoint - February 25, 2021.
| 0 |
LPTX
|
Biliary tract cancer (BTC)
|
Phase 1/2
|
2018-12-14 00:00:00
|
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
| 0 |
BMY
|
Multiple Myeloma
|
Phase 3
|
2020-03-09 00:00:00
|
Phase 3 trial did not meet progression-free survival primary endpoint.
| 1 |
ENTA
|
Hepatitis C virus (HCV)
|
Approved
|
2017-08-03 00:00:00
|
Approval announced August 3, 2017.
| 1 |
NRXP
|
COVID-19
|
Phase 2/3
|
2021-10-14 00:00:00
|
Data from ineligible subjects for the Phase 2b/3 trial recorded a 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment, noted October 14, 2021.
| 1 |
PFE
|
Obsessive compulsive disorder (OCD)
|
Phase 2/3
|
2020-06-24 00:00:00
|
Phase 2/3 top-line data did not meet primary endpoint.
| 1 |
JAZZ
|
Small cell lung cancer (SCLC)
|
Phase 3
|
2020-12-03 00:00:00
|
Phase 3 trial did not meet overall survival endpoint - December 3, 2020.
| 1 |
FBIO
|
Non-small cell lung cancer (NSCLC)
|
Phase 1/2
|
2018-09-25 00:00:00
|
Phase 1/2 preliminary data released September 24, 2018.
| 0 |
CDXS
|
Phenylketonuria (PKU)
|
Phase 1
|
2018-11-08 00:00:00
|
Phase 1 trial met endpoints - November 8, 2018.
| 0 |
AZN
|
COVID-19 vaccine (variant)
|
Phase 2/3
|
2022-02-10 00:00:00
|
Phase 2/3 trial met primary endpoint, noted February 10, 2022.
| 0 |
SCPH
|
Chronic heart failure
|
Phase 2
|
2022-07-12 00:00:00
|
Phase 2 trial data reported a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to "treatment as usual" at day 30, noted July 12, 2022.
| 1 |
SNPX
|
Multiple sclerosis (MS)
|
Phase 1
|
2023-07-19 00:00:00
|
IND submitted to FDA, noted July 19, 2023
| 0 |
EXEL
|
Solid Tumors
|
Phase 1/2
|
2022-01-18 00:00:00
|
Phase 1/2 cohort results showed that of the 36 patients enrolled in cohort 2 of the CAMILLA trial, 29 were evaluable for the efficacy analysis. The primary outcome of investigator-assessed ORR per modified RECIST version 1.1 was 27.6%. The confirmed PR rate was 20.7%, and the DCR was 86.2%. Median PFS was 3.8 months, with a 6-month PFS of 34.5%. Median OS was 9.1 months, noted January 18, 2022.
| 1 |
OPTN
|
Nasal polyps
|
Approved
|
2017-09-17 00:00:00
|
Approval announced September 18, 2017 (prior to IPO).
| 1 |
IPSEY
|
Fibrodysplasia ossificans progressiva (FOP)
|
Approved
|
2023-08-16 00:00:00
|
FDA Approved on August 16, 2023.
| 1 |
CHRS
|
Wet age-related macular degeneration (wAMD), among others
|
Approved
|
2022-08-02 00:00:00
|
Biosimilar approved August 2, 2022.
| 1 |
ADVM
|
Wet age-related macular degeneration (Wet-AMD)
|
Phase 2
|
2022-11-04 00:00:00
|
Phase 2 end-of-study results reported that all 2E11 participants were inflammation free at the end of the study, noted November 4, 2022.
| 0 |
JNJ
|
Relapsing multiple sclerosis
|
Phase 3
|
2019-07-26 00:00:00
|
Phase 3 trial met primary endpoint.
| 0 |
NKTR
|
Renal Cell Carcinoma (RCC)
|
Phase 3
|
2022-04-14 00:00:00
|
Phase 3 data reported that trial did not met its endpoints of objective response rate (ORR) and overall survival (OS), noted April 14, 2022.
| 0 |
ONCT
|
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
|
Phase 1/2
|
2022-12-12 00:00:00
|
Phase 1/2 data reported that the ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of 66% and CR rate of 20% for ibrutinib monotherapy, noted December 12, 2022,
| 1 |
RGNX
|
Homozygous familial hypercholesterolemia (HoFH)
|
Phase 1/2
|
2020-08-06 00:00:00
|
Development to be discontinued - noted August 6, 2020.
| -1 |
SGEN
|
Frontline Hodgkin lymphoma
|
Approved
|
2018-04-04 00:00:00
|
sBLA approval announced March 20, 2018.
| 1 |
PFE
|
Glioblastoma (GBM)
|
Phase 2/3
|
2023-10-31 00:00:00
|
Phase 2/3 data reported that it did not perform better than the current standards of care in glioblastoma, noted October 31, 2023.
| 0 |
NVS
|
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
|
Approved
|
2017-06-22 00:00:00
|
FDA Approval announced June 22, 2017.
| 1 |
MDGL
|
Heterozygous familial hypercholesterolemia (HeFH)
|
Phase 2a
|
2018-04-03 00:00:00
|
Phase 2 top-line data released February 8, 2018 - primary endpoint met.
| 0 |
BPMC
|
Non-advanced systemic mastocytosis (SM)
|
Approved
|
2023-05-22 00:00:00
|
FDA approval on May 22, 2023.
| 1 |
BGNE
|
Waldenström’s macroglobulinemia
|
Approved
|
2021-09-01 00:00:00
|
FDA Approval announced September 1, 2021.
| 1 |
MOR
|
Ulcerative colitis
|
Phase 2b
|
2022-10-24 00:00:00
|
Phase 2b study data reported that treatment led to a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24, noted October 24, 2022.
| 1 |
TAK
|
Complex Crohn's Perianal Fistulas (CPF)
|
Phase 3
|
2023-10-18 00:00:00
|
Phase 3 trial did not meet its primary endpoint, noted October 18, 2023.
| 1 |
AZN
|
Type 2 diabetes
|
Approved
|
2019-05-03 00:00:00
|
FDA approval announced May 3, 2019.
| 1 |
ALT
|
Non-alcoholic steatohepatitis (NASH) - Healthy, Overweight and Obese Volunteers
|
Phase 2
|
2023-03-21 00:00:00
|
Phase 2 interim 24-week data data showed that approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at the 1.8 mg and 2.4 mg doses at Week 24. Treatment discontinuation rates were 28.2% in subjects receiving placebo and 24.0% in subjects receiving pemvidutide, noted March 21, 2023.
| 1 |
EYEN
|
Mydriasis (office-based pupil dilation)
|
Approved
|
2023-11-02 00:00:00
|
FDA supplemental approval on November 1, 2023.
| 1 |
GMAB
|
Relapsing multiple sclerosis
|
Approved
|
2020-08-20 00:00:00
|
FDA approval announced August 20, 2020.
| 1 |
VCNX
|
Resectable Stage III melanoma
|
Phase 1
|
2022-11-10 00:00:00
|
Phase 1 data presented at SITC showed that 100% of patients who received the triple combination were recurrence free at 24 months. This contrasted with recurrence free survival of less than 40% in patients who received the dual combination of pepinemab and nivolumab or pepinemab and ipilimumab, noted November 10, 2022.
| 1 |
CGEN
|
Ovarian Cancer
|
Phase 1
|
2022-11-07 00:00:00
|
Preliminary Phase 1 data reported a 12% ORR in 3L+ MSS-CRC patients with liver metastases, noted November 7, 2022.
| 0 |
LLY
|
Type 2 Diabetes
|
Approved
|
2020-01-27 00:00:00
|
FDA Approval announced January 27, 2020.
| 1 |
AZN
|
Third-line ovarian cancer
|
Phase 3
|
2018-12-20 00:00:00
|
Phase 3 data released December 20, 2018 met primary and secondary endpoints.
| 0 |
VIR
|
COVID-19 antibody
|
Approved
|
2022-02-11 00:00:00
|
EUA granted by FDA February 11, 2022.
| 0 |
CNCE
|
Alopecia areata
|
Phase 3
|
2022-11-21 00:00:00
|
Additional data reported that for patients with an absolute Severity of Alopecia Tool (SALT) score less than 95 at baseline, 43% and 57% of the 8 mg twice-daily and 12 mg twice-daily deuruxolitinib dose groups, respectively, achieved a SALT score of 20 or less at Week 24, noted November 21, 2022.
| 1 |
LXRX
|
Heart failure
|
Approved
|
2023-05-26 00:00:00
|
Approved May 26, 2023.
| 1 |
VRTX
|
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
|
Approved
|
2015-03-17 00:00:00
|
Approved March 17, 2015.
| 1 |
TAK
|
Eosinophilic esophagitis
|
CRL
|
2021-12-21 00:00:00
|
CRL December 21, 2021.
| 0 |
GSK
|
Multiple Myeloma
|
Phase 3
|
2022-11-07 00:00:00
|
Phase 3 trial did not meet its primary endpoint, noted November 7, 2022.
| 1 |
CYTO
|
COVID-19
|
Phase 1
|
2023-01-24 00:00:00
|
Phase 1 topline data reported that trial did not meet primary endpoint, noted January 24, 2023.
| 1 |
ALGS
|
Hepatitis B
|
Phase 1
|
2023-06-21 00:00:00
|
Phase 1 data presented at EASL resulted in dose-dependent reductions in HBsAg levels through 90 days. Importantly, the safety and PK profile of these dose levels also support further evaluation of higher dose levels, noted June 21, 2023.
| 1 |
BLUE
|
Sickle Cell Disease
|
Phase 3
|
2021-02-16 00:00:00
|
Phase 3 trial temporarily suspended due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML) - February 16, 2021.
| 0 |
PFE
|
Acute myeloid leukemia (AML)
|
Approved
|
2018-11-21 00:00:00
|
FDA approval announced November 21, 2018.
| 1 |
AZN
|
Anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG)
|
Approved
|
2022-04-28 00:00:00
|
Approved April 28, 2022.
| 1 |
JAZZ
|
Multiple sclerosis (MS)-related spasticity
|
Phase 3
|
2022-06-28 00:00:00
|
Phase 3 trial did not meet the primary endpoint, noted June 28, 2022.
| 1 |
HOTH
|
EGFRI-induced skin toxicity
|
Phase 2a
|
2023-06-14 00:00:00
|
Received written approval from the Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001, noted June 14, 2024.
| 1 |
ABBV
|
Crohn’s Disease
|
Approved
|
2022-06-17 00:00:00
|
Approved June 17, 2022.
| 1 |
FOLD
|
Pompe Disease
|
Approved
|
2023-09-28 00:00:00
|
FDA Approved on September 28, 2023.
| 1 |
NUVL
|
ALK non-small cell lung cancer (NSCLC)
|
Phase 1
|
2023-10-13 00:00:00
|
Phase 1 trial showed preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and lorlatinib, have brain metastases, or have single or compound ALK resistance mutations, noted October 13, 2023.
| 1 |
BMY
|
Follicular lymphoma
|
Phase 2
|
2023-06-17 00:00:00
|
Phase 2 data presented at ICML showed that 97% of patients with R/R FL treated with Breyanzi achieved a response, with 94% achieving a complete response, and 81.9% of responders in ongoing response at 12 months, noted June 17, 2023.
| 1 |
CRDF
|
Small cell lung cancer (SCLC)
|
Phase 2
|
2023-09-26 00:00:00
|
Phase 2 safety data from the first six patients by the institutional review board confirmed the trial can continue to enroll as planned, noted September 26, 2023.
| 0 |
IKNA
|
Solid tumors and urothelial carcinoma, bladder cancer
|
Phase 1
|
2022-11-10 00:00:00
|
Phase 1 data presented at SITC showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma. Monotherapy activity observed; confirmed partial response with DoR of 14.9 months and ongoing, noted November 10, 2022.
| 1 |
GILD
|
Hepatitis C virus (HCV)
|
Approved
|
2017-07-18 00:00:00
|
Approval announced July 18, 2017.
| 1 |
NGM
|
Pancreatic Cancer
|
Phase 1b
|
2021-09-16 00:00:00
|
Phase 1b data had all 6 patients demonstrated disease control, 3 patients had partial responses (PR), and 3 stable disease (SD). 2 patients discontinued early due to gemcitabine/Nab-paclitaxel toxicity and/or progression of the underlying disease. Phase 1a monotherapy cohort reported 3 patients (30%) in the 30 mg dosing and 2 patients (20%) in the 100 mg dosing had stable disease (SD), September 16, 2021.
| 1 |
GLPG
|
Cutaneous lupus erythematosus (CLE)
|
Phase 2
|
2019-10-24 00:00:00
|
Phase 2 trial did not meet primary endpoint.
| 1 |
BGNE
|
Stage II-IIIA non-small cell lung cancer (NSCLC)
|
Phase 3
|
2023-10-23 00:00:00
|
Phase 3 data presented at ESMO reported that MPR & pCR rates were significantly improved with TIS + CT vs CT, noted October 23, 2023.
| 1 |
LGVN
|
Hypoplastic Left Heart Syndrome
|
Phase 1b
|
2023-05-09 00:00:00
|
Phase 1b long term data reported that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-B, noted May 9, 2023.
| 0 |
RHHBY
|
Pemphigus vulgaris
|
Phase 3
|
2019-06-13 00:00:00
|
Phase 3 trial met primary and secondary endpoints - June 13, 2019.
| 0 |
JNJ
|
Influenza
|
Phase 2a
|
2023-06-22 00:00:00
|
FDA has granted Fast Track designation (FTD), noted June 22, 2023.
| 0 |
OMER
|
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 1b
|
2023-11-02 00:00:00
|
Phase 1b data from ASH abstract reported that mean Hgb increased from baseline by 3.1 g/dL at 4 weeks, and by 9.5 g/dL at the latest timepoint of 24 weeks, noted November 2, 2023.
| 0 |
LLY
|
Diabetes
|
Approved
|
2020-06-15 00:00:00
|
FDA Approval announced June 15, 2020.
| 1 |
ATOS
|
Breast cancer
|
Phase 2
|
2021-06-09 00:00:00
|
Phase 2 final data presented June 9, 2021. Primary endpoint met.
| 1 |
JANX
|
Metastatic castration-resistant prostate cancer (mCPRC)
|
Phase 1
|
2023-07-17 00:00:00
|
Phase 1 interim clinical data showed tumor-activated T cell engagement in patients with prostate cancer representing the first-in-human data for the TRACTr platform and providing confidence for continuing clinical development of JANX007 and advancing future programs from the platform, noted July 17, 2023.
| 1 |
JNJ
|
Waldenström’s Macroglobulinemia
|
Approved
|
2018-08-27 00:00:00
|
FDA approval announced August 27, 2018.
| 1 |
BIIB
|
Postpartum Depression
|
Approved
|
2023-08-04 00:00:00
|
Approved August 4, 2023.
| 1 |
MRK
|
Metastatic Melanoma
|
Phase 2b
|
2023-10-31 00:00:00
|
Phase 2b data presented at SITC reported that a pronounced and ongoing tumor reduction was observed in a patient with progressive disease, noted October 31, 2023.
| 1 |
ZVRA
|
Niemann-Pick disease Type C (NPC)
|
CRL
|
2021-06-18 00:00:00
|
CRL issued June 18, 2021.
| 0 |
ONCY
|
HR+ / HER2- breast cancer
|
Phase 2
|
2023-06-05 00:00:00
|
Phase 2 data readout at ASCO reported that nine pts (33%) discontinued pelareorep and 6 (35%) discontinued avelumab due to toxicity, noted June 5, 2023.
| -1 |
OBSV
|
In Vitro Fertilization (IVF)
|
Phase 3
|
2018-02-26 00:00:00
|
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.
| 1 |
BIVI
|
Alzheimer's disease
|
Phase 2
|
2022-12-05 00:00:00
|
Additional Phase 2 data reported that 18 of 22 patients with abnormal baseline scans showed improvement in one or more brain regions as seen from advanced functional MRI studies, noted December 5, 2022.
| 1 |
ADVM
|
Diabetic macular edema (DME)
|
Phase 2
|
2021-10-09 00:00:00
|
Phase 2 data from trial (June 22, 2021, cutoff date, n=34) at ASRS demonstrated that dose and disease state appear to have an impact in determining the therapeutic window which balances efficacy and safety. Dose-dependent inflammation observed may be in part related to the study population which included patients with severe vascular and renal disease. Further drug development will focus on wet AMD and low doses (2 x 10^11 vg/eye and lower) - noted October 9, 2021
| 1 |
TSVT
|
Multiple Myeloma
|
Phase 3
|
2023-02-10 00:00:00
|
Full Phase 3 data presented at EBMT-EHA 5th European CAR T-cell meeting demonstrated more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma, risk of disease progression or death was reduced by 51% versus standard regimens, noted February 10, 2023. Phase 3 topline results reported that trial met primary endpoint, noted September 7, 2022.
| 1 |
RETA
|
CKD Patients at Risk of Rapid Progression
|
Phase 2
|
2023-05-10 00:00:00
|
Program discontinued, noted May 10, 2023.
| -1 |
CUE
|
HPV16+ head and neck cancer
|
Phase 1
|
2023-11-03 00:00:00
|
Phase 1 data shared at SITC showed an overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) HNSCC patients treated with CUE-101 and pembrolizumab. ORR of 56% in patients with low expression of PD-L1 in the tumor, noted November 3, 2023.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.